financetom
Business
financetom
/
Business
/
Market Chatter: ARM Holdings Cancels Architectural License Agreement With Qualcomm
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: ARM Holdings Cancels Architectural License Agreement With Qualcomm
Oct 23, 2024 2:45 AM

05:27 AM EDT, 10/23/2024 (MT Newswires) -- ARM Holdings ( ARM ) has canceled its architectural license agreement with Qualcomm ( QCOM ) as the companies remain in a legal dispute, Bloomberg News reported Wednesday, citing a document.

According to the report, Arm has sent Qualcomm ( QCOM ) the required 60-day notice to cancel the license deal that allows the latter to use Arm's intellectual property in designing its own chips.

Bloomberg said the license cancellation escalates an ongoing legal dispute between the companies, dating back to 2022 when Arm sued Qualcomm ( QCOM ) for trademark infringement and breach of contract.

Arm Holdings ( ARM ) declined to comment on the matter, while Qualcomm ( QCOM ) did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 152.40, Change: -0.18, Percent Change: -0.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Sep 10, 2025
ZURICH and NESS ZIONA, Israel, Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSPW) (NLS), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and Kadimastem Ltd. ( KMSTF ) (Kadimastem ( KMSTF )), an advanced clinical-stage cell therapy company progressing treatments for neurodegenerative diseases and diabetes, today announced that the U.S. Securities and Exchange Commission (the...
Form 8.3 - Dowlais Group PLC
Form 8.3 - Dowlais Group PLC
Sep 10, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3 - Bakkavor Group PLC
Form 8.3 - Bakkavor Group PLC
Sep 10, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3 - Deliveroo PLC
Form 8.3 - Deliveroo PLC
Sep 10, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved